Get the Stockscreener App
13.49
1.28%
-0.175
After Hours:
13.45
-0.04
-0.30%
Cadrenal Therapeutics Inc stock is traded at $13.49, with a volume of 23,227.
It is down -1.28% in the last 24 hours and down -4.87% over the past month.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
See More
Previous Close:
$13.66
Open:
$13.55
24h Volume:
23,227
Relative Volume:
0.82
Market Cap:
$27.61M
Revenue:
-
Net Income/Loss:
$-4.85M
P/E Ratio:
-43.52
EPS:
-0.31
Net Cash Flow:
$-3.95M
1W Performance:
+2.98%
1M Performance:
-4.87%
6M Performance:
-17.99%
1Y Performance:
-23.35%
1-Day Range:
$13.10
$13.63
1-Week Range:
$12.71
$13.75
52-Week Range:
$8.74
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
13.49 | 27.97M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
What the charts say about Cadrenal Therapeutics Inc. todayShort Setup & Weekly Chart Analysis and Guides - newser.com
What institutional flow reveals about Cadrenal Therapeutics Inc.2025 Market Overview & Long-Term Growth Stock Strategies - newser.com
Why Cadrenal Therapeutics Inc. stock could see breakout soonTreasury Yields & Stepwise Trade Signal Guides - newser.com
Measuring Cadrenal Therapeutics Inc.’s beta against major indicesMarket Risk Analysis & Stock Portfolio Risk Management - newser.com
Will Cadrenal Therapeutics Inc. see short term momentumWeekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Price momentum metrics for Cadrenal Therapeutics Inc. explainedMarket Performance Summary & Risk Controlled Swing Alerts - newser.com
Is Cadrenal Therapeutics Inc. stock cheap compared to fundamentals2025 Market Overview & Verified Swing Trading Watchlists - newser.com
Is Cadrenal Therapeutics Inc. trending in predictive chart modelsMarket Rally & Weekly Breakout Opportunity Watchlist - newser.com
What to do if you’re stuck in Cadrenal Therapeutics Inc.2025 Bull vs Bear & Smart Money Movement Tracker - newser.com
Applying Elliott Wave Theory to Cadrenal Therapeutics Inc.Trade Exit Summary & Verified Entry Point Signals - newser.com
Quantitative breakdown of Cadrenal Therapeutics Inc. recent moveTrade Risk Summary & Safe Entry Momentum Tips - newser.com
Cadrenal Therapeutics Inc Stock Analysis and ForecastEarnings Beat Highlights & The Best Picks Hiding in Plain Sight - earlytimes.in
Applying chart zones and confluence areas to Cadrenal Therapeutics Inc.Weekly Investment Recap & Fast Gain Stock Trading Tips - newser.com
Is Cadrenal Therapeutics Inc. stock a good choice for value investors2025 Volatility Report & Verified Entry Point Detection - newser.com
Kuick Research Releases Landmark Study On US Orphan Drug Rare Disease Market Highlighting Investment And Innovation Opportunities Through 2030 - Benzinga
Combining machine learning predictions for Cadrenal Therapeutics Inc.July 2025 Weekly Recap & Accurate Buy Signal Notifications - newser.com
Viridian Therapeutics (NASDAQ:VRDN) Director Acquires $9,999,990.00 in Stock - Defense World
Why Cadrenal Therapeutics Inc. stock is rated strong buy2025 Earnings Impact & Fast Moving Trade Plans - newser.com
Insider Sell: Matthew Szot Sells Shares of Cadrenal Therapeutics Inc (CVKD) - GuruFocus
Cadrenal Therapeutics Executives Sell Shares - TradingView
CVKD CFO reports 3,600-share sale; 9,933 shares remain - Stock Titan
CVKD insider Quang Pham reports sales under Rule 10b5‑1 plan - Stock Titan
Can Cadrenal Therapeutics Inc. stock reach $100 price target2025 Trading Recap & Fast Entry Momentum Trade Alerts - fcp.pa.gov.br
History Review: Will Cadrenal Therapeutics Inc. stock outperform value stocksJuly 2025 Analyst Calls & Long-Term Capital Growth Ideas - Fundação Cultural do Pará
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):